DPDeirdre R. Pachman

Deirdre R. Pachman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Deirdre R. Pachman has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lessons Learned From Implementing a Complex Cancer Symptom Monitoring Intervention With Electronic Patient Reported Outcome Measures, Electronic Clinician Decision Support, and Remote Collaborative Care Components

    by Sarah A. Minteer, Jennifer L. Ridgeway, Jessica D. Austin, Joan M. Griffin, Nathan K. Tesch, Amanda M. Nelson, Donna M. Dozois, Cindy Tofthagen, Sarah M. Burke, Robert R. McWilliams, et al.

  • Open Access

    Effect of a Symptom Surveillance and Collaborative Care Intervention on Palliative Care Utilization

    by Deirdre R. Pachman, Kathryn J. Ruddy, Joan M. Griffin, Veronica Grzegorczyk, Cindy Tofthagen, Jennifer L. Ridgeway, Jacob Strand, Kurt Kroenke, Linda L. Chlan, Kostantinos Leventakos, et al.


  • Sustainability of Complex Interventions: Recommendations from a Pragmatic Clinical Trial to Manage Cancer Symptoms.

    by Linda L Chlan, Jennifer L Ridgeway, Kathryn J Ruddy, Jessica D Austin, Sandra A Mitchell, Cindy Tofthagen, Deirdre R Pachman, Andrea L Cheville

    Sustained implementation of evidence-based practices and interventions in clinical settings is essential to ensure patients receive the best evidence-informed care. Information to guide sustainment of complex, multi-component interventions in routine clinical practice after grant funding ends has had limited attention in the literature.ObjectivesThe purpose of this article is to describe the efforts of our multidisciplinary trial team to foster sustainment of key components of a complex electronic health record (EHR)-facilitated symptom surveillance and management intervention for people receiving cancer care at a Midwestern quaternary medical center or community practice settings. The parent Enhanced EHR-facilitated Cancer Symptom Control (E2C2) hybrid type II effectiveness-implementation pragmatic trial assessed the effectiveness of a multi-component EHR-facilitated, collaborative care model-based intervention for management of SPPADE symptoms (Sleep interference, Pain, impaired Physical function, Anxiety, Depression, and Energy deficit/fatigue), and its implementation in medical oncology and community practice settings. The Dynamic Sustainability Framework (DSF) posits the need for on-going efforts to continuously optimize the fit of an intervention within dynamic and evolving delivery contexts. This Brief Report uses the DSF to describe our team's efforts to optimize the fit of the core E2C2 intervention components to the practice setting and broader ecological system during the conduct of the trial. These activities were designed to achieve sustained implementation of the intervention in routine care delivery as the funded research activities concluded. Core intervention components to be sustained were symptom surveillance using electronic patient-reported outcome measures, clinician alerts for severe symptoms, access to a registered nurse symptom care manager (RN SCM) for severe symptoms, patient education materials to support symptom self-management, access to a website of cancer-related materials, and the training and supervision of the RN SCMs. Sustainability is dynamic, multidimensional and emphasizes the importance of optimizing the fit of key intervention components to the care delivery context as it evolves time. Investigators are advised to plan sustainability efforts early, embrace change inherent in dynamic settings, and carefully track adaptations of intervention components to maximize intervention fit in real-world clinical practice to ensure patients continue to derive benefit from evidence-informed care.

  • Open Access

    From reporting to relating: Reimagining ePROMs in cancer symptom management

    by Karen S. Schaepe, Joan M. Griffin, Jennifer L. Ridgeway, Deirdre R. Pachman, Kathryn J. Ruddy, Sarah Minteer, Sandra A. Mitchell, Lila J. Finney-Rutten, Andrea L. Cheville


  • Open Access

    Resilient living program for patients with advanced cancer and their caregivers

    by Sherry Chesak, Lori Rhudy, Susanne M. Cutshall, Konstantinos Leventakos, Cindy Tofthagen, Jay Mandrekar, Teresa A. Rummans, Matthew M. Clark, Shawna Ehlers, Maria I. Lapid, et al.

    Objectives: Patients with advanced cancer and their caregivers experience a substantial amount of anxiety and distress. The purpose of this study was to assess the feasibility, acceptability, and preliminary effects of an 8-week, remotely delivered Resilient Living Program (RLP) for adult patients with advanced cancer and their caregivers. Methods: Eligible patients included adults (≥18 years) with advanced cancer. Their caregiver had the option to participate. The RLP components included online modules, a print journal, and 4 video-telehealth-delivered sessions. Content focused on techniques for managing stress and building resilience (mindful presence, uplifting emotions, reframing experiences through practicing principles of gratitude, compassion, acceptance, meaning, and forgiveness). Feasibility and acceptability were assessed quantitatively and with semi-structured interviews conducted with a subset of participants. Effectiveness measures (anxiety, stress, quality of life [QOL], sleep, resiliency, and fatigue) were administered at baseline, week 5, week 9, and week 12. Results: Of the eligible patients, 33/72 (46%) were enrolled. In all, 15 caregivers enrolled. Thirty participants (21 patients/9 caregivers) completed at least 3 video-telehealth sessions (63% adherence). For patients, there were statistically significant improvements in anxiety and fatigue at week 12 (p = 0.05). Other effectiveness measures (stress, QOL, sleep, resiliency) showed positive trends. Eleven participants were interviewed and qualitative analysis revealed 4 themes: Easy to Use, Learning Key Principles, Practice is Essential, and Examples of Benefits. Significance of results: Participation in the RLP was feasible and acceptable for patients with advanced cancer and their caregivers. Participants tended to indicate that the practices were easy to integrate into their everyday lives, engendered their ability to focus on the positive, and would recommend the RLP to other individuals living with advanced cancer. Preliminary effectiveness data suggest the program may positively impact anxiety, stress, QOL, sleep, resiliency, and fatigue. A larger randomized clinical trial is warranted to confirm these preliminary findings.


  • Open Access

    Tracking activities and adaptations in a multi-site stepped wedge pragmatic trial of a cancer symptom management intervention

    by Jennifer L. Ridgeway, Andrea L. Cheville, Kristin J. Fischer, Nathan K. Tesch, Jessica D. Austin, Sarah A. Minteer, Deirdre R. Pachman, Linda L. Chlan, Kathryn J. Ruddy, Joan M. Griffin


  • Open Access

    Table of Contents

    by Kurt Kroenke, Veronica Lam, Kathryn J. Ruddy, Deirdre R. Pachman, Alyson Gundry, Takashi Yamaguchi, Ryo Matsunuma, Yoshinobu Matsuda, Junichi Tasaki, Tomoo Ikari, et al.

  • Open Access

    I suffer too

    by Deirdre R. Pachman

  • Pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU RU221408I.

    by Deirdre R. Pachman, Travis J. Dockter, Patricia J. Zekan, Briant Fruth, Kathryn Jean Ruddy, Lauren E. Ta, Todor Dentchev, Nguyet Le-Lindqwister, William M. Sikov, Charles L. Loprinzi

    220 Background: Paclitaxel is associated with both an acute pain syndrome (P-APS) and chronic chemotherapy-induced peripheral neuropathy (CIPN). Preliminary animal data suggest that minocycline may be effective for the prevention of chemotherapy-induced neurotoxicity. The purpose of this pilot study was to investigate the efficacy of minocycline for the prevention of CIPN and P-APS. Methods: Patients with breast cancer were enrolled prior to initiating neoadjuvant or adjuvant weekly paclitaxel for 12 weeks. They were randomized to receive minocycline 200mg on day 1 followed by 100mg twice daily or a placebo, with the same dosing schedule. Patients completed (1) an acute pain syndrome questionnaire daily during chemotherapy, and (2) the EORTC QLQ-CIPN20 questionnaire at baseline, prior to each dose of paclitaxel, and monthly for 6 months post treatment. The primary goal was to obtain pilot data regarding the possible effect of minocycline on the prevention of paclitaxel-induced CIPN and P-APS, to determine if conducting a larger phase III placebo-controlled trial was indicated. Scores obtained from patient questionnaires were converted to a 0-100 scale, where higher scores = better quality of life. Results: Forty-seven patients were randomized, 45 of which were evaluable, with a mean age of 55. There were no remarkable differences noted between the two groups for the overall sensory score of the EORTC-CIPN 20 or its individual sub-questions, which evaluated tingling, numbness, or shooting burning pain in hands and feet. However, there was a significant difference in the daily average AUC pain score attributed to P-APS, favoring minocycline (median 96.0 vs 84.3; p = 0.02). Correspondingly, patients receiving minocycline used less opioid pain medications for control of P-APS (0% vs 23%, P = 0.05). Not only were no increased toxicities reported with minocycline, but there was an apparent improvement in fatigue (median AUC 76.7 vs 59.0; P = 0.02). Conclusions: Based on the results of this pilot study, minocycline did not appear to be beneficial for the prevention of CIPN, but did look promising for reducing P-APS. Further study of this effect may be warranted. Clinical trial information: NCT02297412.

  • Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505)

    by Deirdre R. Pachman, Rui Qin, Drew Seisler, Ellen M. Lavoie Smith, Suneetha Kaggal, Paul Novotny, Kathryn J. Ruddy, Jacqueline M. Lafky, Lauren E. Ta, Andreas S. Beutler, et al.

    Purpose Oxaliplatin and paclitaxel are commonly used chemotherapies associated with acute and chronic neuropathies. There is a need to better understand the similarities and differences of these clinical syndromes. Methods Neuropathy data were pooled from patients receiving adjuvant oxaliplatin and weekly paclitaxel or every 3 weeks of paclitaxel. Patients completed daily questionnaires after each chemotherapy dose and the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for patients with chemotherapy-induced peripheral neuropathy before each chemotherapy cycle and for 12 months post-treatment. Results Acute neuropathy symptoms from both drugs peaked around day 3. Acute symptoms experienced in cycle 1 predicted occurrence in subsequent cycles. Paclitaxel-induced acute symptoms were similar in intensity in each cycle and largely resolved between cycles. Oxaliplatin-induced acute symptoms were about half as severe in the first cycle as in later cycles and did not resolve completely between cycles. Both drugs caused a predominantly sensory chronic neuropathy (with numbness and tingling being more common than pain). Oxaliplatin-induced neuropathy worsened after the completion of treatment and began to improve 3 months post-treatment. In contrast, paclitaxel-induced neuropathy began improving immediately after chemotherapy cessation. During treatment, the incidence of paclitaxel sensory symptoms was similar in the hands and feet; with oxaliplatin, the hands were affected more than the feet. Both paclitaxel- and oxaliplatin-induced acute neurotoxicity appeared to predict the severity of chronic neuropathy, more prominently with oxaliplatin. Conclusions Knowledge of the similarities and differences between neuropathy syndromes may provide insight into their underlying pathophysiology and inform future research to identify preventative treatment approaches.